Literature DB >> 208077

Vasoactive intestinal peptide: a potent stimulator of adenosine 3':5'-cyclic monophosphate accumulation in gut carcinoma cell lines in culture.

M Laburthe, M Rousset, C Boissard, G Chevalier, A Zweibaum, G Rosselin.   

Abstract

Vasoactive intestinal peptide (VIP) is a potent and efficient stimulator of adenosine 3':5'-cyclic monophosphate (cAMP) accumulation in a human colon carcinoma cell line, HT 29. cAMP accumulation is sensitive to a concentration of VIP as low as 3x10(-12) M. Maximum VIP-induced cAMP levels were observed with 10(-9) M VIP and are about 200 times above the basal levels. Half-maximum cAMP production was obtained at 3x10(-10) M VIP. (125)I-Labeled VIP was found to bind to HT 29 cells; this binding was competitively inhibited by concentrations of unlabeled VIP between 10(-10) and 10(-7) M. Half-maximum inhibition of binding was observed with 2x10(-9) M VIP. Secretin also stimulated cAMP accumulation in HT 29 cells, but its effectiveness was 1/1000 that of VIP. The other peptides tested at 10(-7) M, such as insulin, glucagon, bovine pancreatic polypeptide, somatostatin, octapeptide of cholecystokinin, neurotensin, and substance P, did not stimulate cAMP accumulation. Prostaglandin E(1) and catecholamines stimulated cAMP production but were 1/2.3 and 1/5.5 as efficient as VIP, respectively. Another malignant cell line from the gut, the human rectal tumor cell line HRT 18, is also sensitive to VIP. In HRT 18 cells, VIP stimulated cAMP accumulation with a maximal effect at 10(-8) M; half-maximum stimulation was observed at about 10(-9) M. These results demonstrate the presence of VIP receptors in two malignant human intestinal cell lines (HT 29 and HRT 18) in culture and provide a model for studying the action of VIP on cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 208077      PMCID: PMC392646          DOI: 10.1073/pnas.75.6.2772

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Immunoassay of endogenous plasma insulin in man.

Authors:  R S YALOW; S A BERSON
Journal:  J Clin Invest       Date:  1960-07       Impact factor: 14.808

2.  Interactions of glucagon, gut glucagon, vasoactive intestinal polypeptide and secretin with liver and fat cell plasma membranes: binding to specific sites and stimulation of adenylate cyclase.

Authors:  D Bataille; P Freychet; G Rosselin
Journal:  Endocrinology       Date:  1974-09       Impact factor: 4.736

3.  Adenylate cyclase activity in adrenocorticotropic hormone-sensitive and mutant adrenocortical tumor cell lines.

Authors:  B P Schimmer
Journal:  J Biol Chem       Date:  1972-05-25       Impact factor: 5.157

4.  Conditions leading to enhanced response to glucagon, epinephrine, or prostaglandins by adenylate cyclase of normal and malignant cultured cells.

Authors:  M H Makman
Journal:  Proc Natl Acad Sci U S A       Date:  1971-09       Impact factor: 11.205

5.  Lipolytic action of a newly isolated vasoactive intestinal polypeptide.

Authors:  E K Frandsen; A J Moody
Journal:  Horm Metab Res       Date:  1973-05       Impact factor: 2.936

6.  T.S.H. receptor and adenylate cyclase in undifferentiated thyroid carcinoma.

Authors:  Y Abe; Y Ichikawa; M Homma; K Ito; T Mimura
Journal:  Lancet       Date:  1977-09-03       Impact factor: 79.321

7.  Differentiation of receptor systems activated by sympathomimetic amines.

Authors:  A M Lands; A Arnold; J P McAuliff; F P Luduena; T G Brown
Journal:  Nature       Date:  1967-05-06       Impact factor: 49.962

8.  Vasoactive intestinal peptide (VIP): variation of the jejuno-ileal content in the developing rat as measured by radioreceptorassay.

Authors:  M Laburthe; D Bataille; G Rosselin
Journal:  Acta Endocrinol (Copenh)       Date:  1977-03

9.  [Intestinal vasoactive peptide receptors in enterocytes : specific binding and stimulation of cyclic AMP].

Authors:  M Laburthe; J Besson; D H Bon Hoa; G Rosselin
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1977-06-06

10.  Localization of vasoactive intestinal polypeptide (VIP) to central and peripheral neurons.

Authors:  L I Larsson; J Fahrenkrug; O Schaffalitzky De Muckadell; F Sundler; R Håkanson; J R Rehfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

View more
  29 in total

1.  Vasoactive intestinal peptide receptors in rat liver after partial hepatectomy.

Authors:  L G Guijarro; A Couvineau; M S Rodriguez-Pena; M G Juarranz; N Rodriguez-Henche; E Arilla; M Laburthe; J C Prieto
Journal:  Biochem J       Date:  1992-07-15       Impact factor: 3.857

2.  Transmitter-induced changes of the membrane voltage of HT29 cells.

Authors:  E Lohrmann; Z I Cabantchik; R Greger
Journal:  Pflugers Arch       Date:  1992-06       Impact factor: 3.657

3.  Phenotype alteration in colon carcinoma cells: effect of in vivo passage?

Authors:  M A Maley; A K House; D J Jenkyn; G Sterrett
Journal:  In Vitro Cell Dev Biol       Date:  1991-05

4.  Simultaneous analysis of cell Ca2+ and Ca2(+)-stimulated chloride conductance in colonic epithelial cells (HT-29).

Authors:  A P Morris; K L Kirk; R A Frizzell
Journal:  Cell Regul       Date:  1990-11

5.  VIP receptors and control of short circuit current in the human intestinal clonal cell line Cl.19A.

Authors:  C Rouyer-Fessard; C Augeron; E Grasset; J J Maoret; C L Laboisse; M Laburthe
Journal:  Experientia       Date:  1989-12-01

6.  Vasoactive intestinal polypeptide: specific binding to rat brain membranes.

Authors:  D P Taylor; C B Pert
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

7.  Antipeptide antibodies to the beta 2-adrenergic receptor confirm the extracellular orientation of the amino-terminus and the putative first extracellular loop.

Authors:  M A Théveniau; J R Raymond; G N Rougon
Journal:  J Membr Biol       Date:  1989-10       Impact factor: 1.843

8.  The effect of secretagogues on ion conductances of in vitro perfused, isolated rabbit colonic crypts.

Authors:  E Lohrmann; R Greger
Journal:  Pflugers Arch       Date:  1995-02       Impact factor: 3.657

Review 9.  Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.

Authors:  S G R Smalley; P A Barrow; N Foster
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

10.  The rat liver vasoactive intestinal peptide binding site. Molecular characterization by covalent cross-linking and evidence for differences from the intestinal receptor.

Authors:  A Couvineau; M Laburthe
Journal:  Biochem J       Date:  1985-01-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.